Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to keep High-Risk leukemia in remission before transplant

NCT ID NCT07425782

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults who have already achieved remission after initial treatment will be randomly assigned to one of the two approaches. The goal is to see which strategy leads to longer leukemia-free survival and fewer side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA CONSOLIDATION THERAPY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) HIGH RISK VENENTOCLAX

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • the First Affiliated Hosptital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.